ClinVar Miner

Submissions for variant NM_014714.4(IFT140):c.2035G>A (p.Gly679Arg)

gnomAD frequency: 0.00003  dbSNP: rs769632242
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001345884 SCV001540031 uncertain significance Saldino-Mainzer syndrome 2021-09-01 criteria provided, single submitter clinical testing This sequence change replaces glycine with arginine at codon 679 of the IFT140 protein (p.Gly679Arg). The glycine residue is weakly conserved and there is a moderate physicochemical difference between glycine and arginine. This variant is present in population databases (rs769632242, ExAC 0.008%). This variant has not been reported in the literature in individuals affected with IFT140-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The arginine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002476593 SCV002788667 uncertain significance Saldino-Mainzer syndrome; Retinitis pigmentosa 80 2021-07-22 criteria provided, single submitter clinical testing
Ambry Genetics RCV004988572 SCV005604233 uncertain significance Inborn genetic diseases 2024-08-01 criteria provided, single submitter clinical testing The c.2035G>A (p.G679R) alteration is located in exon 17 (coding exon 15) of the IFT140 gene. This alteration results from a G to A substitution at nucleotide position 2035, causing the glycine (G) at amino acid position 679 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.